Apidra

Land: Den Europæiske Union

Sprog: engelsk

Kilde: EMA (European Medicines Agency)

Aktiv bestanddel:

insulin glulisine

Tilgængelig fra:

sanofi-aventis Deutschland GmbH

ATC-kode:

A10AB06

INN (International Name):

insulin glulisine

Terapeutisk gruppe:

Drugs used in diabetes

Terapeutisk område:

Diabetes Mellitus

Terapeutiske indikationer:

Treatment of adults, adolescents and children, six years or older with diabetes mellitus, where treatment with insulin is required.

Produkt oversigt:

Revision: 32

Autorisation status:

Authorised

Autorisation dato:

2004-09-27

Indlægsseddel

35
B. PACKAGE LEAFLET
36
PACKAGE LEAFLET: INFORMATION FOR THE USER
APIDRA 100 UNITS/ML SOLUTION FOR INJECTION IN A VIAL
Insulin glulisine
_ _
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Apidra is and what it is used for
2.
What you need to know before you use Apidra
3.
How to use Apidra
4.
Possible side effects
5.
How to store Apidra
6.
Contents of the pack and other information
1.
WHAT APIDRA IS AND WHAT IT IS USED FOR
Apidra is an antidiabetic agent, used to reduce high blood sugar in
patients with diabetes mellitus; it
may be given to adults, adolescents and children, 6 years of age and
older. Diabetes mellitus is a
disease where your body does not produce enough insulin to control the
level of blood sugar.
It is made by biotechnology. It has a rapid onset within 10-20 minutes
and a short duration, about 4
hours.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE APIDRA
DO NOT USE APIDRA
-
If you are allergic to insulin glulisine or any of the other
ingredients of this medicine (listed in
section 6).
-
If your blood sugar is too low (hypoglycaemia), follow the guidance
for hypoglycaemia (see
box at the end of this leaflet).
WARNINGS AND PRECAUTIONS
Talk to your doctor, pharmacist or nurse before using Apidra.
Follow closely the instructions for dose, monitoring (blood tests),
diet and physical activity (physical
work and exercise) as discussed with your doctor.
Special patient groups
If you have liver or kidney problems, speak to your doctor as you may
need a lower dose.
There is insuff

Produktets egenskaber

1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Apidra 100 Units/ml solution for injection in a vial
Apidra 100 Units/ml solution for injection in a cartridge
Apidra SoloStar 100 Units/ml solution for injection in a pre-filled
pen
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains 100 Units insulin glulisine (equivalent to 3.49 mg).
_ _
_Apidra 100 Units/ml solution for injection in a vial _
Each vial contains 10 ml of solution for injection, equivalent to 1000
Units.
_ _
_Apidra 100 Units/ml solution for injection in a cartridge _
Each cartridge contains 3 ml of solution for injection, equivalent to
300 Units.
_ _
_Apidra SoloStar 100 Units/ml solution for injection in a pre-filled
pen _
Each pen contains 3 ml of solution for injection, equivalent to 300
Units.
Insulin glulisine is produced by recombinant DNA technology in
_Escherichia coli_
.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
_Apidra 100 Units/ml solution for injection in a vial _
Solution for injection in a vial.
_Apidra 100 Units/ml solution for injection in a cartridge _
Solution for injection in a cartridge.
_Apidra SoloStar 100 Units/ml solution for injection in a pre-filled
pen _
Solution for injection in a pre-filled pen.
Clear, colourless, aqueous solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of adults, adolescents and children 6 years or older, with
diabetes mellitus, where treatment
with insulin is required.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The potency of this preparation is stated in units. These units are
exclusive to Apidra and are not the
same as IU or the units used to express the potency of other insulin
analogues (see section 5.1).
Apidra should be used in regimens that include an intermediate or long
acting insulin or basal insulin
analogue and can be used with oral hypoglycaemic agents.
The dose of Apidra should be individually adjusted.
3
Special populations
_Renal impairment _
The pharmacokinetic properties of insulin